leisure time -WSS

leisure time

author：knowledge 2025-10-04 11:50:23 - browse：31

Two people stare at a keyhole in a human head in between them, as the short-haired person on the left holds a key — first opinion coverage from STAT — Adobe

In many ways, psychiatry is still flying blind. People experiencing mental health conditions are prescribed various drugs until one (or a combination) finally works — a painful process that can take years. As a psychiatrist and neuroscientist, I became increasingly impatient and frustrated with this ineffective way of treating patients. This guided the core question behind my research: Can biology explain how people with the same psychiatric disorder respond differently to the same treatment?

Since I first began exploring this question more than a decade ago, mental illness has become a global epidemic. Despite significant efforts, progress in psychiatric drug development has remained disappointingly slow. There have been a few notable approvals in recent years, and a renewal of interest by Big Pharma, following a retreat from psychiatric research in the mid to late 2000s. But the landscape remains predominantly marked by failures and a dry drug development pipeline. Approved drugs follow the same pattern of prescribing via guesswork, with most patients not responding to a given drug. This cycle of trial-and-error drug development producing trial-and-error treatment arises from a simple source: We have not systematized a process for learning from our failures and successes.

Related: A ‘renaissance in neuroscience’ could deliver a fresh crop of psychiatric medicines

For example, take depression: While the rise of selective serotonin reuptake inhibitors (SSRIs) in the 1980s and 1990s seemed to provide a solution, seminal studies in the 2000s exposed fundamental limitations of our treatment options. Antidepressants are widely prescribed, but their efficacy relative to placebo is modest.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Moonlake's readout produced a cash windfall. Risks remain

WSS

As AI in medicine takes off, can 'human in the loop' prevent harm?

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

Steward Health Care Massachusetts hospitals face fiscal disaster

Readout Newsletter: CAR

How to save health care price transparency rules

Novavax promises a turnaround & Lilly roils the obesity market

hotspot

leisure time

Related: A ‘renaissance in neuroscience’ could deliver a fresh crop of psychiatric medicines

knowledge

In Memoriam: Notable people who died in 2023

Sports medicine is finally prioritizing gender equality

Hepatitis C has a cure — but many Americans still lack access to it

How to save health care price transparency rules

Apple is now the first public company to be valued at $3 trillion

In Memoriam: Notable people who died in 2023

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

First U.S. drug developed to treat liver disease MASH is approved

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Tori Bowie and the unacceptable rates of Black maternal death

knowledge

Medicare details structure of new drug price negotiation program

Amid AI frenzy, a top HHS official's quest to create safeguards

Dobbs anniversary: the lost opportunity of abortion as health care

Dobbs anniversary: the lost opportunity of abortion as health care

UCLA team creates talking throat patch for voice disorders

FDA approval of Sarepta Duchenne genetic therapy gives me hope

focus

entertainment

Wikipedia

Wikipedia